Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Wearable sensor may replace the dreaded glucose drink test for gestational diabetes

NCT ID NCT06357728

Diagnosis Sponsor: KK Women's and Children's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This study tests whether a continuous glucose monitor (CGM) worn on the arm can diagnose gestational diabetes as well as the standard oral glucose tolerance test (OGTT). Pregnant women of Chinese or Indian ethnicity will wear the sensor for up to 10 days and also undergo the OGTT. Researchers will compare glucose readings from both methods and see which better predicts pregnancy outcomes. The goal is to find a more comfortable and informative way to diagnose gestational diabetes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Continuous glucose monitoring (CGM) sensor (Dexcom G6)
What this could lead to
If successful, this could lead to a more comfortable and detailed way to diagnose gestational diabetes, potentially replacing the oral glucose tolerance test.
What could go wrong
This is a small pilot study, so results may not apply to all populations. The CGM sensor may cause skin irritation, and its accuracy compared to the standard test is still unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 45 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Pregnant women of only Chinese or Indian ethnicity 2. Pregnant women between age 21--45 years old 3. Oral glucose tolerance test (OGTT) to be scheduled between 20-35 weeks gestational age 4. OGTT to be done at KK Women's and Children's Hospital Exclusion Criteria: 1. Women with serious skin conditions (e.g. eczema) that precludes wearing the sensor for 10 days 2. Exclusion criteria were pre-existing Type 1 or Type 2 diabetes, mental illness precluding informed consent and women who were diagnosed early (1st or early 2nd trimester for GDM).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gestational diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gestational diabetes glucose metabolism disease metabolic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gestational diabetes Glucose metabolism disorders Metabolic disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • KK Women's and Children's Hospital

    RECRUITING

    Singapore, Singapore, 229899, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.